Candriam Luxembourg S.C.A. grew its holdings in Radius Health Inc (NASDAQ:RDUS) by 37.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 195,000 shares of the biopharmaceutical company’s stock after acquiring an additional 53,000 shares during the period. Candriam Luxembourg S.C.A. owned 0.44% of Radius Health worth $6,195,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. California Public Employees Retirement System grew its position in Radius Health by 2.3% in the fourth quarter. California Public Employees Retirement System now owns 74,400 shares of the biopharmaceutical company’s stock worth $2,364,000 after acquiring an additional 1,700 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in Radius Health in the fourth quarter worth approximately $353,000. Alps Advisors Inc. bought a new stake in shares of Radius Health during the 4th quarter worth $1,570,000. Mutual of America Capital Management LLC boosted its holdings in shares of Radius Health by 45.6% during the 4th quarter. Mutual of America Capital Management LLC now owns 49,615 shares of the biopharmaceutical company’s stock worth $1,576,000 after buying an additional 15,534 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its holdings in shares of Radius Health by 0.9% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 182,575 shares of the biopharmaceutical company’s stock worth $5,801,000 after buying an additional 1,674 shares during the period.
Several analysts recently issued reports on RDUS shares. Cantor Fitzgerald set a $58.00 price objective on shares of Radius Health and gave the stock a “buy” rating in a report on Thursday, December 7th. Citigroup reaffirmed a “hold” rating and set a $43.00 price objective on shares of Radius Health in a report on Monday, January 22nd. BidaskClub raised shares of Radius Health from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a report on Monday, January 8th. Finally, Jefferies Group decreased their price objective on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $51.78.
In related news, major shareholder Growth N. V. Biotech bought 75,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was purchased at an average cost of $34.38 per share, for a total transaction of $2,578,500.00. Following the purchase, the insider now directly owns 5,773,799 shares in the company, valued at $198,503,209.62. The purchase was disclosed in a filing with the SEC, which is available through this link. 15.00% of the stock is owned by corporate insiders.
Shares of Radius Health Inc (NASDAQ:RDUS) opened at $38.57 on Friday. The stock has a market cap of $1,720.00, a price-to-earnings ratio of -7.10 and a beta of 1.21. Radius Health Inc has a 1-year low of $24.66 and a 1-year high of $49.16. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87.
ILLEGAL ACTIVITY WARNING: This story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thelincolnianonline.com/2018/02/16/candriam-luxembourg-s-c-a-acquires-53000-shares-of-radius-health-inc-rdus.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health Inc (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.